Nektar Therapeutics Files 8-K on Financials
Ticker: NKTR · Form: 8-K · Filed: Aug 7, 2025 · CIK: 906709
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: NKTR
TL;DR
Nektar filed an 8-K on Aug 7, 2025, updating financials. Details to come.
AI Summary
Nektar Therapeutics filed an 8-K on August 7, 2025, reporting on its results of operations and financial condition, and including financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text.
Why It Matters
This filing indicates Nektar Therapeutics is providing updates on its financial status and operational results to the SEC, which is crucial for investors to assess the company's performance.
Risk Assessment
Risk Level: low — The filing is a standard corporate disclosure and does not inherently present new risks.
Key Players & Entities
- Nektar Therapeutics (company) — Registrant
- August 7, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 455 Mission Bay Boulevard South (address) — Principal Executive Offices
- San Francisco (city) — Principal Executive Offices
- California (state) — Principal Executive Offices
- 94158 (zip_code) — Principal Executive Offices
FAQ
What specific financial results are being reported by Nektar Therapeutics in this 8-K?
The provided text indicates the filing pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not detail specific financial figures.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on August 7, 2025.
What is Nektar Therapeutics' state of incorporation?
Nektar Therapeutics is incorporated in Delaware.
Where are Nektar Therapeutics' principal executive offices located?
Nektar Therapeutics' principal executive offices are located at 455 Mission Bay Boulevard South, San Francisco, California 94158.
What is the Commission File Number for Nektar Therapeutics?
The Commission File Number for Nektar Therapeutics is 000-24006.
Filing Stats: 505 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2025-08-07 16:26:08
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value NKTR Nasdaq Capital Marke
Filing Documents
- ea0252183-8k_nektar.htm (8-K) — 24KB
- ea025218301ex99-1_nektar.htm (EX-99.1) — 80KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-25-073100.txt ( ) — 279KB
- nktr-20250807.xsd (EX-101.SCH) — 3KB
- nktr-20250807_lab.xml (EX-101.LAB) — 33KB
- nktr-20250807_pre.xml (EX-101.PRE) — 22KB
- ea0252183-8k_nektar_htm.xml (XML) — 3KB
02 Results of Operations and Financial
Item 2.02 Results of Operations and Financial Condition. On August 7, 2025, Nektar Therapeutics, a Delaware corporation ("Nektar"), issued a press release (the "Press Release") announcing its financial results for the quarter ended June 30, 2025. A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report, including the exhibit hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by Nektar, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release titled "Nektar Therapeutics Reports Second Quarter 2025 Financial Results." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEKTAR THERAPEUTICS Date: August 7, 2025 By: /s/ Mark A. Wilson Mark A. Wilson Chief Legal Officer and Secretary 2